Current Value Frameworks – What's New?

Patrick Gleason, PharmD
Prime Therapeutics
Eagan, MN, USA

ISPOR Summit
New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare

Patrick Gleason, PharmD, FCCP, FAMCP, BCPS
Senior Director, Health Outcomes
Value ASSESSMENT

Sustainable Access to High Value Care for All Patients

Long term Value for Money
- Clinical outcomes
- Comparative effectiveness

Short Term Pharmacy Spend
- Total Cost of Care
- Persistency/Adherence
- Potential Budget Impact
- Forecasting Med/Rx Data

EVOLUTION OF TWO VALUE BASED CONTRACTING MODELS

Understanding populations is vital in engaging in Value based contracts

One Course of Therapy
- Curative therapies
- Very high cost burden
- Ability to track effectiveness, side effects via registries
- Durability uncertainty

Chronic Lifetime Therapy
- Larger populations
- Longer horizon to track population and outcomes (e.g. slower disease progression, events)
- Balance of short and long term financial benefits
- Persistency and adherence required to achieve outcomes
VALUE BASED CONTRACTING: DEFINED

Data and Analytics form the foundation of Value Based Contracts

Outcomes-based
Discounts based on pre-determined clinical outcomes
  e.g. HbA1c, adherence, prevalence of events

Financial-based
Discounts linked to utilization or other financial factors
  e.g. PMPM, capitation, indication-based, total cost of care.

Health Monitoring & Diagnostic Testing
Appropriate Therapy & Adherence
Health Outcomes & Overall Total Cost of Care

Data Analytics (e.g. Condition Identification, Risk Scoring)

1 CareCentered Contracting™ can be synonymous with market terms such as Value, Outcomes, Quality based contracting

Using icer report to determine value threshold

Multiple Sclerosis DMD Self-Administered
Average Annual Actual Cost $80,073 from ICER 2017 Report

$80,073
$23,679
$16,015
$6,000
$20,779

$30,379 annual MS DMD price for value
At $150,000 investment per quality of life year (QALY) gained

$28,015 available manufacturer cost discount
Real world data assessment of ms dmd drug effectiveness and cost

Association Between Adherence to Multiple Sclerosis (MS) Disease Modifying Drug (DMD) Therapy and Moderate to Severe Relapses in a Cohort of Commercial Members Followed for Three Years

Objective: Establish an estimate of the direct medical cost offset associated with adherence to MS DMD therapy.

Of 4 million continuously enrolled members, 4753 met MS criteria and had a DMD in year 0, of whom 2859 (60.2%) were adherent and 1894 (39.8%) were not adherent over years 1 to 3. Over the 3 years, 520 (18.2%) of the adherent and 471 (25.2%) of the not adherent had a moderate or severe relapse (relapse among adherent odds ratio 0.672, 95% confidence interval 0.584 to 0.774).

Findings:
• Prime found the average allowed medical expense per MS relapse was $9,000.
• MS DMD therapy adherence for 3 years was associated with a 7 percentage point decrease in members with claims indicating an MS relapse.
• To prevent relapse in 1 MS member saving $9,000 in medical costs, 15 members currently non-adherent to DMD therapy for three years would need to be adherent.
• It will cost $3 million in new DMD expenditures to get 15 members adherent.

Conclusion: An investment of $333 in MS DMD cost is needed to save $1 in direct medical MS relapse cost avoided. This information helps inform clinical program and pharmaceutical value-based contracting assessments.